Anika Therapeutics, Inc. announced that it has appointed Steve Griffin as the Company?s Chief Financial Officer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition.

Steve Griffin brings more than 15 years of experience in senior finance leadership roles and a proven track record of value creation at both large- and small-cap companies. Steve most recently served as Senior Vice President and Chief Financial Officer at VSE Corporation, where he helped orchestrate and execute a strategic transformation of a 60 year-old company through organic growth, six acquisitions, and two divestitures. In this role he was responsible for all finance, investor relations and corporate IT functions.

Prior to his tenure with VSE Corporation, Mr. Griffin spent over a decade at General Electric in positions of increasing responsibility including Corporate Audit, Financial Planning and Analysis, and Divisional CFO roles. At GE, Steve worked across GE Healthcare, GE Aerospace, and GE Power, and he is also a graduate of GE?s financial management program. Mr. Griffin holds a B.S. in Finance and Accounting from Boston College and an M.B.A. from the University of Michigan.